Yong Dai

Yong Dai has served as our Chief Technology Officer since 2019. He joined Prevail in 2018 as the Senior Vice President of Gene Therapy, bringing more than 17 years of biotechnology industry experience focused on bioprocess development, chemistry, manufacturing and controls (CMC), good manufacturing practice (GMP), process validation, and regulatory submissions, including extensive work with gene therapy drug development. Prior to joining Prevail, Yong was the Senior Director of Process Development at uniQure, where he was responsible for process and analytical development and manufacturing sciences for early and late stage gene therapy drug development programs. Prior to his time at uniQure, he served as the Head of Process Development Commercial Support at Shire Pharmaceuticals and held senior CMC roles at ImmunoGen. Yong completed his postdoctoral research at Harvard University, and holds a Ph.D. in biochemistry and molecular biology from the Chinese Academy of Sciences. He also holds an M.S. in biochemistry and molecular biology and a B.S. in biochemistry from the Peking University in China.